GSK boss rethinking R&D incentives, as Barron and Sin seek out early and late-stage ops

GlaxoSmithKline CEO Emma Walmsley has been in the hot seat for around a year, and while announcing the company's first-quarter results this week had new CSO Hal Barron by her side, as the two hinted at possible changes in R&D incentives, and what another new hire made last week could bring to the pipeline.